Cardiorenal safety and efficacy of angiotensin receptor-neprilysin inhibitors in heart failure across the ejection fraction spectrum: A meta-analysis and meta-regression of RCTs with 28,001 patients.

ABSTRACT: Angiotensin receptor-neprilysin inhibitors (ARNIs), including sacubitril/valsartan, exert blood pressure-lowering and organ-protective effects in patients with heart failure (HF). However, differences of these effects across HF phenotypes and their impact on renal outcomes remain unclear. The present systematic review aimed to evaluate the antihypertensive efficacy, safety and cardiorenal benefits of ARNIs vs. angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) in patients with HF with reduced, mildly reduced, and preserved ejection fractions. Data were extracted from PubMed, Scopus, Cochrane, ProQuest and Google Scholar up to July 2025. Risk of bias was evaluated using the Cochrane Risk of Bias 2 tool. Meta-analyses were performed using risk ratios (R

SUBMITTER: Rampengan DDCH 

PROVIDER: S-EPMC12715665 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature